Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors.

It targets the TWEAK receptor.

[1] Enavatuzumab was developed by Facet Biotech Corp.[2]

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.